Longitudinal trajectory of frailty in blood or marrow transplant survivors: Report from the Blood or Marrow Transplant Survivor Study.
cohort study
frailty
hematopoietic stem cell transplantation
long-term survivors
longitudinal trajectory
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
22
04
2020
revised:
31
07
2020
accepted:
27
08
2020
pubmed:
19
11
2020
medline:
16
10
2021
entrez:
18
11
2020
Statut:
ppublish
Résumé
Blood or bone marrow transplantation (BMT) survivors with frailty are at a higher risk of subsequent mortality. Longitudinal trends in the frailty state are not known and could help identify vulnerable subpopulations at risk of subsequent adverse events. This study included a cohort of 470 autologous and allogeneic BMT recipients who had survived ≥2 years after BMT and completed a baseline questionnaire (t1) at a median of 7.3 years after BMT and a follow-up questionnaire (t2) 13.2 years after t1. The main outcome was change in frailty state between t1 and t2. Frailty phenotype was defined as exhibiting ≥3 of the following characteristics: clinically underweight, exhaustion, low energy expenditure, slow walking speed, and muscle weakness. The following categories of change in frailty state were evaluated: worsened, improved, and stable. Of the 470 participants, 36.4% were aged ≥60 years at t1, and 50.6% were men. The prevalence of frailty increased from 4.8% at t1 to 9.6% at t2. Worsening was observed in 18.8% of patients, and improvement was reported in 9.7%. Pre-BMT exposure to vincristine (odds ratio [OR], 2.1; 95% CI, 1.3-3.39) was associated with worsening. Female sex (OR, 1.5; 95% CI, 0.93-2.4) was associated with a trend toward worsening. Pre-BMT exposure to vincristine (OR, 2.79; 95% CI, 1.44-5.43), a history of chronic graft-versus-host disease (OR, 2.58; 95% CI, 1.2-5.5), and grade 3 and 4 chronic health conditions at t1 (OR, 2.1; 95% CI, 1.08-4.33) were associated with frailty at t2. In a cohort of BMT survivors who were followed longitudinally for a median of 20.6 years from BMT, the frailty status worsened for approximately20% over a 13-year timespan. BMT survivors who are at risk for worsening frailty could benefit from targeted interventions.
Sections du résumé
BACKGROUND
Blood or bone marrow transplantation (BMT) survivors with frailty are at a higher risk of subsequent mortality. Longitudinal trends in the frailty state are not known and could help identify vulnerable subpopulations at risk of subsequent adverse events.
METHODS
This study included a cohort of 470 autologous and allogeneic BMT recipients who had survived ≥2 years after BMT and completed a baseline questionnaire (t1) at a median of 7.3 years after BMT and a follow-up questionnaire (t2) 13.2 years after t1. The main outcome was change in frailty state between t1 and t2. Frailty phenotype was defined as exhibiting ≥3 of the following characteristics: clinically underweight, exhaustion, low energy expenditure, slow walking speed, and muscle weakness. The following categories of change in frailty state were evaluated: worsened, improved, and stable.
RESULTS
Of the 470 participants, 36.4% were aged ≥60 years at t1, and 50.6% were men. The prevalence of frailty increased from 4.8% at t1 to 9.6% at t2. Worsening was observed in 18.8% of patients, and improvement was reported in 9.7%. Pre-BMT exposure to vincristine (odds ratio [OR], 2.1; 95% CI, 1.3-3.39) was associated with worsening. Female sex (OR, 1.5; 95% CI, 0.93-2.4) was associated with a trend toward worsening. Pre-BMT exposure to vincristine (OR, 2.79; 95% CI, 1.44-5.43), a history of chronic graft-versus-host disease (OR, 2.58; 95% CI, 1.2-5.5), and grade 3 and 4 chronic health conditions at t1 (OR, 2.1; 95% CI, 1.08-4.33) were associated with frailty at t2.
CONCLUSIONS
In a cohort of BMT survivors who were followed longitudinally for a median of 20.6 years from BMT, the frailty status worsened for approximately20% over a 13-year timespan. BMT survivors who are at risk for worsening frailty could benefit from targeted interventions.
Identifiants
pubmed: 33206383
doi: 10.1002/cncr.33313
pmc: PMC8833138
mid: NIHMS1776369
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
794-800Subventions
Organisme : NCI NIH HHS
ID : R01 CA078938
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA213140
Pays : United States
Organisme : Leukemia and Lymphoma Society
ID : R6502-16
Informations de copyright
© 2020 American Cancer Society.
Références
Geriatr Gerontol Int. 2018 Nov;18(11):1549-1555
pubmed: 30221449
N Engl J Med. 2002 Oct 3;347(14):1068-74
pubmed: 12362007
J Clin Oncol. 2013 Dec 20;31(36):4496-503
pubmed: 24248696
Bone Marrow Transplant. 2000 Jun;25(11):1191-6
pubmed: 10849532
J Gerontol A Biol Sci Med Sci. 2004 Mar;59(3):255-63
pubmed: 15031310
Bone Marrow Transplant. 2012 Feb;47(2):283-90
pubmed: 21423125
Am J Med. 2015 Nov;128(11):1225-1236.e1
pubmed: 26159634
J Am Med Dir Assoc. 2016 May 1;17(5):426-33
pubmed: 26947059
JAMA. 1990 Jun 13;263(22):3029-34
pubmed: 2342214
Lancet Public Health. 2018 Jul;3(7):e323-e332
pubmed: 29908859
Clin Geriatr Med. 2018 Feb;34(1):25-38
pubmed: 29129215
J Clin Oncol. 2020 Jan 20;38(3):232-247
pubmed: 31800343
J Am Geriatr Soc. 2019 Jun;67(6):1145-1151
pubmed: 30891748
Gerontology. 2009;55(5):539-49
pubmed: 19346741
JAMA Oncol. 2016 Oct 1;2(10):1277-1286
pubmed: 27254472
Exp Gerontol. 2017 Mar;89:30-40
pubmed: 28043934
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156